Amarillo, Texas,November 3, 2011 — Amarillo Biosciences, Inc. (ABI) (OTCBB: AMAR) announced today that a new audio interview with ChartPoppers.com is now available (AMAR). ABI is developing low-dose oral interferon for human and animal health. The product is safe, inexpensive, stable at room temperature, and easy-to-administer; and it works by modulating the immune system to help regulate interferon sensitive genes. The company asserts that low dose oral interferon can achieve many of the benefits of high dose injectable interferon without the side effects commonly seen when patients are given large doses of interferon by injection. In the interview, the VP for Clinical and Regulatory Affairs provides an update on the Company's ongoing clinical trials, including the soon-to-be completed Phase 2 dose-ranging study in Taiwan that is testing the ability of low-dose oral IFN to reduce the virologic relapse rate in hepatitis C patients. Relapse in hepatitis C patients following standard treatment is a major health problem that could be addressed by the Company's technology.
ChartPoppers.com is a small-cap research and investment commentary provider. ChartPoppers.com strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on ChartPoppers, please visit http://ChartPoppers.com/.
ChartPoppers.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. ChartPoppers.com is a Web site wholly owned by Seo Freisin, Inc. ChartPoppers.com nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. Please read our report and visit our Web site, ChartPoppers.com, for complete risks and disclosures.
About Amarillo Biosciences
Amarillo Biosciences, Inc. is a U.S. biotechnology firm operating in global partnership with the Hayashibara Group, which also holds 6% of Amarillo Biosciences shares and has provided over $18 million in loans, grants and equity investments. The Company's primary focus is extensive and ongoing R&D into the use of low-dose, orally administered interferon as a treatment for a variety of conditions, including influenza, hepatitis C, chronic cough, and opportunistic infections in patients who are HIV positive. The Company has invested nearly $40 million to establish oral interferon as a therapeutic agent. The majority of those funds were invested in clinical trials in an effort to achieve FDA approval for interferon. Additional information is available on the web at http://www.amarbio.com/. Except for the historical information contained herein, the matters discussed in this news release are forward-looking statements that involve risks and uncertainties, including uncertainties related to product development, uncertainties related to the need for regulatory and other government approvals, dependence on proprietary technology, uncertainty of market acceptance of oral interferon or the Company's other product candidates and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission. In particular, see "Item 1. Description of Business" and "Item 7A. Qualitative and Quantitative Disclosures about Market Risk" of the Company's Form 10-K for the fiscal year ended December 31, 2010.